In states of sodium deficiency many animals seek and consume salty 25 solutions to restore body fluid homeostasis. These behaviors reflect the presence 26 of sodium appetite which is a manifestation of the pattern of activity in central 27 nervous system (CNS) circuitry that has both facilitatory and inhibitory components 28 and is controlled by several neuro-humoral factors. The primary focus of this 29 review is on one structure in this central system, the lateral parabrachial nucleus 30 (LPBN). However, before turning to a more detailed discussion of the LPBN, a brief 31 overview of body fluid balance-related body-to-brain signaling and the identification 32 of the primary CNS structures and humoral factors involved in the control of 33 sodium appetite is necessary. Angiotensin II, mineralocorticoids and extracellular 34 osmotic changes act on forebrain areas to facilitate sodium appetite and thirst. In 35 the hindbrain, the LPBN functions as a key integrative node with an ascending 36 output that exerts inhibitory influences on forebrain regions. A nonspecific or 37 general deactivation of LPBN-associated inhibition by GABA or opioid agonists 38 produces NaCl intake in euhydrated rats without any other treatment. Selective 39 LPBN manipulation of other neurotransmitter systems (e.g., serotonin, CCK, CRH, 40 glutamate, ATP, or noradrenaline) greatly enhances NaCl intake when 41 accompanied by additional treatments that induce either thirst or sodium appetite. 42
Introduction 49
Animals constantly lose water and electrolytes to the external environment, 50 but specific autonomic, hormonal and behavioral mechanisms operate 51 continuously to adjust and restore body fluid-electrolyte balance. The rate of loss 52 from the kidneys is primarily controlled by neural and hormonal actions, but loss 53 may also occur passively through the largely uncontrolled processes of respiration 54 (evaporation), perspiration, transpiration and salivation. These later modes of loss 55 are referred to as insensible loss because they cannot be easily measured. Severe 56 loss of both sodium and water may also occur in disorders associated with emesis 57 and diarrhea. However, in spite of such ongoing challenges, the osmolarity and 58 volume of body fluids are maintained within reasonably narrow limits, thus allowing 59 normal metabolic and cardiovascular functions. Although renal mechanisms can 60 slow water and sodium loss, the restoration of fluid homeostasis is only made 61 possible by the mobilization of behaviors that result in the ingestion of water and 62 sodium (usually NaCl). The behavioral responses of seeking out and consuming 63 water and salty substances involve the motivational states of thirst and salt 64 appetite. Salt appetite, is also frequently referred to as sodium appetite, and salt or 65 sodium hunger. The state of sodium appetite can be experimentally induced, 66 tested and operationally defined by the ingestion of hypertonic NaCl solutions (in 67 most cases 0.3 or 0.5 M NaCl) at concentrations that are usually aversive to rats in 68 sodium balance (5, 50, 76, 77) . 69
The behavioral, endocrine and autonomic mechanisms that control sodium 70 balance involve an extensive central circuitry comprised of both forebrain and 71 hindbrain structures (5, 50, 76, 77, 120). Within this brain circuitry, the lateral 72 9 injections of ANP conjugated to the cytotoxin ricin, increase hypertonic NaCl intake 169 in response to ANG II or hypovolemia (14, 56) . 170
171

Central α 2 adrenergic mechanisms 172
Noradrenaline acting centrally has a dual role in the control of sodium and 173 water intake. Acting on forebrain α 1 -or hindbrain α 2 -adrenoceptors, noradrenaline 174 facilitates both behaviors. In contrast, acting on forebrain α 2 -adrenoceptors 175 noradrenaline inhibits them (10, 11, 28, 40, 93, 125) . Similar to noradrenaline, 176 either icv or forebrain parenchimal injections into the lateral hypothalamus, medial 177 septal area or preoptic area of α 2-adrenoceptor agonists (e.g., α-178 methylnoradrenaline) or of α 2 -adrenergic/imidazoline receptor agonists (e.g., 179
clonidine or moxonidine) also inhibit water and sodium intake (39, 40, 47, 93, 125) . 180
The effects of α 2 -adrenoceptor or α 2 -adreno/imidazoline receptor agonists on 181 sodium and water intake are reversed by the pre-treatment with α 2 -adrenoceptor 182
antagonists (e.g., yohimbine, RX 821002 or SK&F86466), which suggests that the 183 activation of α 2 -adrenoceptors plays a role in the inhibition of water and sodium 184 intake (40, 47, 93, 125). The increased efficacy provided by the imidazoline moiety 185 to several α 2 -adrenoceptor agonists and antagonists suggests a synergic action 186 between imidazoline receptors and α 2 -adrenoceptors acting to inhibit water and 187 salt intake (40, 93, 125) . 188
Peripheral administration of clonidine and moxonidine also inhibits water 189 and sodium intake, whereas peripheral administration of yohimbine has the 190 opposite effect (40, 57, 93, 132 Drinking studies in the pigeon suggest that an homologous serotonergic system 203 inhibits fluid intake in both birds and mammals (18). Consistent with the inhibitory 204 effect that serotonin receptor activation has on sodium appetite, early studies also 205
showed that when given systemically, agonists that reduce serotonin release or 206
antagonists that act on 5HT 2 receptors increase sodium intake (29, 114). 207
Studies showing enhanced sodium intake in rats with electrolytic or ibotenic 208 acid lesions in the dorsal raphe nucleus (DRN), suggest that the DRN is a source 209 of endogenous serotonin that inhibits salt appetite (20, 21). Such inhibition is 210 possibly linked to reduced ANP release and modulation of forebrain activity in 211 circumventricular organs (9, 87, 109, 110). Moreover, in sodium depleted rats, the 212 ingestion of hypertonic or isotonic saline results in reduced activity in serotonin 213 neurons of the DRN (54, 69). Together these results suggest that DRN 214 serotonergic neurons are associated with the process of satiating sodium appetite. isoproterenol or icv relaxin usually only elicit water intake, they induce a significant 327 sodium appetite when combined with LPBN methysergide injections (88, 89, 92). 328
It is important to emphasize that bilateral LPBN injections of methysergide 329 by itself in fluid replete rats produces no water or hypertonic NaCl intake. This 330 indicates that only blocking the action of serotonin in the LPBN without the 331 presence of some type of facilitating factor is not sufficient to induce sodium or 332 water intake. On the other hand, sodium intake is easily generated when 333 attenuation of LPBN serotonergic inhibitory mechanisms is combined with either a 334 dipsogenic or a natriorexigenic stimulus. This suggests that the LPBN acts strongly 335 to inhibit sodium intake (27, 90-92, 94, 96) . 
animals. 367
It is possible that the manipulation of those neurotransmitters/receptors 368 which require the synergistic assistance of accompanying dehydration or sodium 369 deficiency does not elicit sodium intake in hydrated animals because, in contrast to 370
GABAergic activation, it does not remove a sufficient amount of tonic inhibition. It 371 seems reasonable to speculate that the manipulation of those 372 neurotransmitters/receptors which require the synergistic assistance of 373 accompanying dehydration or sodium deficiency would be effective in fluid replete 374 rats if a critical number of other restraining inhibitory influences were also blocked. 375
Without sufficient suppression of multiple inhibitory influences that converge on the 376 LPBN, the threshold for removing the tonic inhibitory influence projected to the 377 forebrain is not reached and sodium intake is not released in fluid replete rats. 
